The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine — this one developed by Moderna for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Authorized Use For the prevention of 2019 coronavir...

The basis of upcoming Pfizer and Moderna coronavirus vaccines. How it works?

Background: mRNA-1273 was developed by Moderna based on prior studies of related coronaviruses such as those that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A Phase 1 trial (NCT04283461) of 105 healthy participants provided the basis for Moderna’s investigational new drug appl...

Moderna’s mRNA vaccine technology offers potential advantages in efficacy, speed of development, and production scalability and reliability. mRNA-based vaccines offer several advantages, including: Ability to mimic many aspects of natural viral infections. mRNA enters cells and is used to produce viral antigen...

The vaccine, known as mRNA-1273, was co-developed by the Cambridge, Massachusetts-based American biotechnology company Moderna, Inc., and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial, which will be conducted at U.S. clinical research sites, is expecte...